Table 3.

COX-2 deficiency increases neonatal mortality and patent DA incidence with Ptgs1 gene dosage-dependent compensation

Offspring genotype	% mortality*	Patent DA,† % incidence
COX-1(+/+)/COX-2(+/+)	3 (1/31)	0 (0/8)
COX-1(+/−)/COX-2(+/+)	6 (3/47)	0 (0/6)
COX-1(−/−)/COX-2(+/+)	3 (1/40)	0 (0/10)
COX-1(+/+)/COX-2(+/−)	4 (2/49)	0 (0/6)
COX-1(+/−)/COX-2(+/−)	1 (1/99)	0 (0/8)
COX-1(−/−)/COX-2(+/−)	3 (3/88)	0 (0/21)
COX-1(+/+)/COX-2(−/−)	35‡ (20/57)	33 (5/15)
COX-1(+/−)/COX-2(−/−)	79‡ (26/33)	74 (14/19)
COX-1(−/−)/COX-2(−/−)	100‡ (38/38)	100 (23/23)

Neonatal mortality for each genotype is the percentage of mice that died during the 48 h following birth compared to the number at birth. Neonatal patent DA incidence was determined 5 h after Cesarean delivery or natural birth on gestation day 19.5. 

^*In parentheses are number dead/number born. 

^† In parentheses are number patent/number analyzed. 

^‡ Significantly different (χ² statistic, P < 0.01).